Wealthspire Advisors (Maryland)’s Galectin Therapeutics GALT Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$37K	Buy	+13,855	New	+$38.8K	﹤0.01%	478

Other funds holding GALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s GALT Position: Q3 2020 in Review

Wealthspire Advisors (Maryland) opened a new position in Galectin Therapeutics (GALT) in Q3 2020: 13,855 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #478 among its holdings.

71 funds tracked by Wall St. Rank hold GALT as of Q3 2020.

Wealthspire Advisors (Maryland) held 13,855 shares of Galectin Therapeutics worth $37K as of Q3 2020.
Galectin Therapeutics was a new Wealthspire Advisors (Maryland) position in Q3 2020.
Galectin Therapeutics made up ﹤0.01% of Wealthspire Advisors (Maryland)'s portfolio in Q3 2020, its #478 holding.
71 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2020.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q3 2020, filed 13 Nov 2020.